Alpha-1 antitrypsin deficiency (AATD) is found to be associated with pregnancy-related complications and adverse birth ...
Fingolimod treatment leads to beneficial effects in Huntington disease (HD), according to a new study in a mouse model of the ...
Vosoritide was approved in 2021, after current achondroplasia guidelines were published, creating a need for treatment and monitoring recommendations. A new international consensus statement has been ...
Overall, 80.9% of patients were in complete remission 1 year after diagnosis irrespective of GPA or MPA cases (79.7% vs 83.8%, respectively). The therapeutic armamentarium for individuals with ...
Overall, the life expectancy of patients with SCD is lower than that of persons without SCD. 1 However, life expectancy varies depending on the type of disease, treatments administered, and ...
There were fewer multiorgan transplants in patients with hereditary ATTR-CM with increased use of disease-modifying therapies, a study found.
The navenibart phase 3 program will consist of the ALPHA-ORBIT phase 3 trial and the long-term extension trial, which are designed to support registration globally. Global start-up activities ...
Nusinersen, an SMN2-targeted antisense oligonucleotide drug administered by intrathecal injection, was able to improve motor function and survival. Treatment with nusinersen can improve motor function ...
The overall survival rate at 18 months for patients diagnosed before the introduction of the new guideline was 79% while it was 90% after the introduction of the guideline. The number of patients ...
Magnetic resonance imaging of the brain and spinal cord revealed lesions typical of patients with MS. The report highlighted the challenges in the diagnosis and management of this type of case, given ...
The adolescent HAE population continue to experience unique challenges to their school and social lives that degrade their health-related quality of life. Adolescents with hereditary angioedema (HAE) ...
A recent analysis of the PEXIVAS trial showed that plasma exchange can significantly improve kidney function in patients with AAV and kidney involvement.